Lebsanan (Tacrolimus)

Tacrolimus binds to the intracellular protein FKBP‑12, forming a complex that inhibits calcineurin. This inhibition blocks interleukin‑2 transcription, reducing T‑cell activation and the downstream inflammatory cascade in the skin.

The prescribed amount is determined by the treating clinician based on disease severity and the area of skin involved. Typically, a thin layer is applied to the affected sites once or twice daily, but exact dosing must follow the prescriber’s instructions.

Safety data for topical tacrolimus in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Healthcare providers should weigh potential benefits against risks and consider alternative therapies when appropriate.

Enquiries can be submitted via the product page on gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lebsanan (tacrolimus) offers a non‑steroidal option that avoids skin thinning associated with potent topical corticosteroids. Compared with pimecrolimus, another calcineurin inhibitor, tacrolimus generally provides stronger immunosuppression and is often chosen for moderate to severe disease.

Store Lebsanan at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct light, and avoid freezing. Do not use the product after the expiration date.

Apply a thin film of the cream or ointment to clean, dry skin on the affected areas. Avoid contact with eyes, mouth and open wounds. Wash hands after application and follow the prescriber’s frequency and duration recommendations.

Serious risks include allergic contact dermatitis, secondary skin infections, severe skin thinning, and, rarely, systemic immunosuppression that could increase susceptibility to infections or malignancies such as lymphoma.

Lebsanan should not be used by individuals with known hypersensitivity to tacrolimus or any formulation excipients, those with active skin infections, or patients with severely compromised immune systems unless specifically directed by a specialist.